IO Biotech to Present at Upcoming Healthcare Conferences
![IO Biotech to Present at Upcoming Healthcare Conferences](https://investorshangout.com/images/blog/ihnews-IO%20Biotech%20to%20Present%20at%20Upcoming%20Healthcare%20Conferences.jpg)
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company dedicated to developing innovative immune-modulating therapeutic cancer vaccines based on the T-win platform, recently announced the upcoming participation of its senior management team in various investor conferences. These engagements will provide insights regarding the company's ongoing projects and future potential.
Details of the Conferences
At the Morgan Stanley 22nd Annual Global Healthcare Conference, taking place shortly, Dr. Mai-Britt Zocca, the CEO of IO Biotech, will participate in a fireside chat scheduled for September 4, 2024, at 5:35 pm ET. This conference represents a significant opportunity for IO Biotech to connect with potential investors and deliver a corporate update directly related to the ongoing developments in their therapeutic offerings.
H.C. Wainwright Conference Participation
Following that, at the H.C. Wainwright 26th Annual Global Investment Conference, Amy Sullivan, CFO of IO Biotech, is scheduled to present the company’s strategic initiatives on September 9, 2024, at 10:30 am ET. This presentation is intended to outline the progress of IO Biotech's pipeline and innovative approaches to cancer treatment.
Accessing the Webcast
A live webcast of these presentations will be available on IO Biotech's official website, offering a chance for interested parties to engage with the content remotely. Following the events, the recording will remain accessible for approximately 90 days, allowing for wider audience participation.
About IO102-IO103
IO102-IO103 is an experimental cancer vaccine designed to engage the immune system in combating both tumor cells and the immunosuppressive cells that impede effective immune responses within the tumor microenvironment (TME). This innovative therapy aims to boost T cell activation against indoleamine 2,3-dioxygenase (IDO) positive and programmed death-ligand 1 (PD-L1) positive cells, which are critical targets in cancer treatment.
Clinical Trials and Partnerships
The clinical trials for IO102-IO103 are currently at pivotal phases. The company is conducting a Phase 3 trial (NCT05155254) comparing the vaccine in combination with pembrolizumab against pembrolizumab alone in patients suffering from advanced melanoma. Additionally, they are engaging in a Phase 2 basket trial (NCT05077709) examining the efficacy as a first-line treatment for patients with a variety of solid tumors, alongside another Phase 2 study (NCT05280314) focused on neo-adjuvant/adjuvant treatments. These studies are sponsored by IO Biotech in collaboration with Merck, which is providing pembrolizumab for the trials.
About IO Biotech
IO Biotech is a forward-thinking clinical-stage biopharmaceutical firm focused on the development of immune-modulating cancer therapies. Their T-win platform offers a fresh perspective on cancer vaccine technology, harnessing the body’s immune response to address tumor-supportive cells. IO Biotech is currently progressing with its lead candidate, IO102-IO103, through clinical trials while also evaluating additional candidates at the preclinical stage.
Based on their promising data from Phase 1/2 trials for metastatic melanoma, IO102-IO103 has received breakthrough therapy designation from the US Food and Drug Administration, enhancing its potential in the oncology landscape. IO Biotech operates globally, with headquarters in Copenhagen and a prominent presence in New York.
Contact Information
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
Email: mci@iobiotech.com
Media
Julie Funesti
Salutem
917-498-1967
Email: Julie.Funesti@salutemcomms.com
Frequently Asked Questions
What is the focus of IO Biotech?
IO Biotech specializes in developing immune-modulating therapeutic cancer vaccines.
When will IO Biotech present at investor conferences?
IO Biotech will participate in the Morgan Stanley Conference on September 4, 2024, and the H.C. Wainwright Conference on September 9, 2024.
How can I access the presentations from IO Biotech?
The webcast of the presentations will be available on IO Biotech's website for 90 days following the events.
What is IO102-IO103?
IO102-IO103 is an investigational therapeutic cancer vaccine targeting tumor cells and immune-suppressive cells in the tumor microenvironment.
Who are IO Biotech's collaborators for clinical trials?
IO Biotech conducts its clinical trials in collaboration with Merck, which supplies pembrolizumab for ongoing studies.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Exela Technologies to Discuss Q2 2024 Financial Results
- August Cash Distributions Announced by BlackRock Canada
- Interoil Exploration Updates on ANH Contracts
- JBDI Holdings Limited Launches $11.25 Million IPO
- Vaso Corporation Announces Stockholder Meeting Update
- Teva to Showcase Innovations at Global Healthcare Conference
- Water Ways Technologies Announces Director Resignation
- Capital Power Launches C$600 Million Notes Offering
- Market Update: Dow Hits Record High Amid Nvidia Earnings
- Understanding the Silver Squatter Phenomenon Among Gen X